15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Oric Pharmaceuticals Inc, 10 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $15.00 to $25.00, a moderate spread. The average target of $19.80 sits 66% above the current $11.93. The rating mix has stayed broadly stable, with Buy-side ratings easing from 11 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.37 next quarter toward $-1.61 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Strong Buy
Strong Buy00%
Buy1091%
Hold19%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Oric Pharmaceuticals Inc.
As of Jul, 10 of 11 firms rate ORIC a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ORIC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.37
Range $-0.45 – $-0.30 · 13 analysts · +13% YoY
Next period, 13 analysts expect Oric Pharmaceuticals Inc to earn $-0.37 a share (range $-0.45 – $-0.30), versus $-0.33 a year earlier. Full-year consensus is $-1.47, growing to $-1.61 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 13 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Oric Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ORIC.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$18.00+50.9% to target
Overall win rate
55%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #62
Buy
No targeton ORIC
Overall win rate
46%
+ Follow
#3
David Nierengarten
Wedbush · Rank #115
Buy
$17.00+42.6% to target
Overall win rate
41%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$16.00+34.2% to target
Overall win rate
43%
+ Follow
#5
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$25.00+109.6% to target
Overall win rate
38%
+ Follow
ORIC stock forecast FAQ
What is ORIC's average 12-month price target?+
The 10 analysts with a live target average $19.80 for Oric Pharmaceuticals Inc over the next 12 months, ranging from a $25.00 high to a $15.00 low.
Is ORIC stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 11 analyst ratings, 10 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ORIC?+
The Street-high target is $25.00 (HC Wainwright & Co.), and the Street-low is $15.00 (Goldman Sachs). The average of all 10 active targets is $19.80.
How many Wall Street analysts cover ORIC?+
11 analysts have an active rating on Oric Pharmaceuticals Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering ORIC?+
Among analysts who currently cover ORIC, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $18.00 target.
What is Oric Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.37 per share (range $-0.45 – $-0.30) across 13 analysts. Full-year EPS is projected at $-1.47, rising to $-1.61 the following year.
How much revenue is Oric Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ORIC lately?+
As of Jul, 10 of 11 firms rate ORIC a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ORIC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
